For my story on single-cell proteomics and massively parallel single-molecule analysis and sequencing, I spoke with many and as usual heard many views. Which is always intriguing. So here are some of the views. @ryankellybyu mentioned there’s a parallel universe of sorts... ...between the mass spectrometry-based single-cell proteomics and non-mass-spec single-molecule methods. These areas and approaches “don’t yet overlap,” says @ryankellybyu . Oh and right I should put in the link to the story. nature.com/articles/s4159…

Podcasters and others: Did a recording with @RiversidedotFM and @Zoom with same person same conditions. Will still check out the files more. First impressions: @RiversidedotFM file has crunchiness and a kind of hum that Zoom recording does not have. I want to like @RiversidedotFM but...am not sure what to make of the audio quality . am exporting with some noise cancellation and will see what that sounds like.

The CRISPR children. rdcu.be/cBYZO My latest story in @NatureBiotech , three years in the making. Thank you so much to those willing to be interviewed. So very many said: Noooo, go away, not taking about that!! Thank you to my editors. My sources. A first 🧵 Yes, a lot of stories have been written about the ‘CRISPR babies,’ who are now three years old. Here is some reading, hardly comprehensive bioengineeringcommunity.nature.com/posts/the-cris…. It surprised me how little focus there was on the children's health and how to assess that.

The report about the CDC SARS-Cov-2 test is out. Plenty went wrong. But the timeline still seems puzzling. In the course of January @WHO began making protocols for molecular tests available. The US authorities decided to use the CDC protocol. 1/n For use at CDC the test worked. A scaled up version of the CDC protocol was made, it seems, at the CDC. These were assays for the public health labs. Much of February was lost due to the tests delivering spurious results. 2/n